Your browser is no longer supported. Please, upgrade your browser.
Settings
RDY Dr. Reddy's Laboratories Limited daily Stock Chart
RDY [NYSE]
Dr. Reddy's Laboratories Limited
Index- P/E30.95 EPS (ttm)1.36 Insider Own27.70% Shs Outstand168.25M Perf Week-6.15%
Market Cap7.08B Forward P/E23.15 EPS next Y1.82 Insider Trans0.00% Shs Float121.69M Perf Month-5.39%
Income226.00M PEG2.44 EPS next Q0.49 Inst Own13.90% Short Float1.03% Perf Quarter3.70%
Sales2.38B P/S2.98 EPS this Y69.20% Inst Trans-3.92% Short Ratio6.64 Perf Half Y20.05%
Book/sh12.51 P/B3.36 EPS next Y-7.95% ROA7.20% Target Price39.21 Perf Year13.18%
Cash/sh1.64 P/C25.70 EPS next 5Y12.70% ROE11.00% 52W Range34.67 - 46.19 Perf YTD3.72%
Dividend0.28 P/FCF17.57 EPS past 5Y-2.10% ROI9.70% 52W High-12.51% Beta0.16
Dividend %0.67% Quick Ratio1.20 Sales past 5Y3.10% Gross Margin54.10% 52W Low16.56% ATR0.91
Employees21966 Current Ratio1.80 Sales Q/Q13.90% Oper. Margin8.60% RSI (14)32.59 Volatility1.83% 1.51%
OptionableYes Debt/Eq0.11 EPS Q/Q-217.70% Profit Margin9.50% Rel Volume1.01 Prev Close42.09
ShortableYes LT Debt/Eq0.01 EarningsJan 27 BMO Payout- Avg Volume189.63K Price40.41
Recom4.00 SMA20-8.96% SMA50-5.15% SMA2003.10% Volume116,438 Change-3.99%
Jan-28-20Downgrade CLSA Buy → Outperform
Jan-27-20Downgrade CLSA Buy → Outperform
Jan-09-20Upgrade Citigroup Sell → Buy
Nov-04-19Downgrade BofA/Merrill Buy → Neutral
Sep-04-19Upgrade Credit Suisse Underperform → Outperform
Jul-01-19Upgrade Macquarie Neutral → Outperform
Jun-20-19Initiated Deutsche Bank Hold
Jun-11-19Initiated Barclays Equal Weight $39
May-20-19Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-19-19Upgrade CLSA Outperform → Buy
Jan-17-19Downgrade Citigroup Neutral → Sell
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-31-17Upgrade CLSA Underperform → Outperform
Jul-28-17Downgrade CLSA Underperform → Sell
Jul-27-16Downgrade Jefferies Hold → Underperform
Jul-27-16Downgrade HSBC Securities Hold → Reduce
Feb-10-16Upgrade Credit Agricole Underperform → Buy
Nov-10-15Downgrade Citigroup Buy → Neutral
Jan-21-11Initiated HSBC Securities Overweight
Jan-19-10Downgrade Deutsche Bank Hold → Sell
Feb-27-20 04:03AM  Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market Business Wire
Feb-14-20 11:41AM  Risks Remain, but Amarin Stock Is a Buy at Todays Prices InvestorPlace
Feb-07-20 03:02AM  Dr. Reddy's Laboratories Announces the Launch of Trientine Hydrochloride Capsules USP, 250 mg, in the U.S. Market Business Wire
Feb-06-20 08:30AM  Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 PR Newswire
Jan-30-20 07:00AM  Dr. Reddy's Selects Kinaxis to Transform Supply Chain and Business Operations CNW Group
Jan-28-20 10:20AM  Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y Zacks
Jan-27-20 04:32AM  Dr. Reddys Q3 & 9M FY20 Financial Results Business Wire +5.29%
03:00AM  Dr. Reddys Laboratories swings to net loss in third quarter MarketWatch
Jan-13-20 01:31PM  Top Pharmaceutical Stocks for Q1 2020 Investopedia
Jan-10-20 10:14AM  New Strong Sell Stocks for January 10th Zacks
07:42AM  Dr. Reddy's to Release Q3 FY 20 results on January 27, 2020  Earnings Call Slated for January 27, 2020 @ 6:30 PM IST / 8:00 AM EST Business Wire
Dec-30-19 04:57AM  Dr. Reddy's Laboratories Announces the Launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial in the U.S. Market Business Wire
Dec-20-19 04:41AM  Amarin Stock is at Sky-High Levels Already Assumes All the Good News InvestorPlace
Dec-13-19 12:00PM  Hedge Funds Are Piling Into Dr. Reddys Laboratories Limited (RDY) Insider Monkey
Dec-06-19 03:29AM  Dr. Reddy's Laboratories Announces the Launch of Deferasirox Tablets for Oral Suspension, in the U.S. Market Business Wire
03:23AM  Dr. Reddy's Laboratories Announces the Launch of Deferasirox Film-Coated Tablets, in the U.S. Market Business Wire
Dec-04-19 02:49AM  Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market Business Wire
Nov-22-19 04:48AM  Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market Business Wire
Nov-15-19 08:42AM  New Strong Sell Stocks for November 15th Zacks
Nov-13-19 09:22AM  New Strong Sell Stocks for November 13th Zacks
Nov-11-19 08:42AM  New Strong Sell Stocks for November 11th Zacks
Nov-04-19 09:10AM  Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y Zacks
Nov-01-19 04:29AM  Dr. Reddys Q2 & H1 FY20 Financial Results Business Wire
Oct-23-19 04:42AM  Dr. Reddys Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market Business Wire
Oct-17-19 04:55PM  Hedge Fund Sentiment Unchanged On Dr. Reddys Laboratories Limited (RDY) Insider Monkey
Oct-14-19 06:40AM  Dr. Reddy's to release Q2 FY 20 results on November 1, 2019 Business Wire
Sep-30-19 05:45PM  Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen Zacks
Sep-23-19 11:18AM  The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power Zacks
08:45AM  BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1% Zacks
Sep-20-19 05:14PM  Foamix Initiates Phase II Study on Acne Combination Foam Zacks
11:17AM  Is it Apt to Foray Into the Indian Stock Market?: An Analysis Zacks
Sep-19-19 11:32AM  J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use Zacks
10:29AM  Zynerba Releases Data on Epilepsy Candidate, Stock Down Zacks
Sep-17-19 11:29AM  Top Ranked Momentum Stocks to Buy for September 17th Zacks
Sep-16-19 10:00AM  What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now? Zacks
03:16AM  Dr. Reddys Announces the Launch of Over-the-Counter, Store-Brand Equivalent of Prevacid® 24HR Capsules (Lansoprazole Delayed-Release Capsules USP, 15 mg) in the U.S. Market Business Wire
Sep-11-19 07:18AM  Dr. Reddy's Laboratories Announces the Launch of Fosaprepitant for Injection in the U.S. Market Business Wire
Sep-06-19 09:07AM  Dr. Reddy's Laboratories Limited to Present at the Morgan Stanley Annual Global Healthcare Conference Business Wire
Sep-04-19 09:15AM  The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's Zacks
Sep-03-19 06:52AM  Top Stories of August Worth Watching in September Zacks
Aug-28-19 08:36AM  5 Stocks From the Best Performing Sectors in Q2 Zacks
Aug-26-19 08:38AM  5 Stock-Picking Strategies to Counter Market Turbulence Zacks
Aug-20-19 02:59AM  Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Powder for Oral Solution, USP in the U.S. Market Business Wire
Aug-19-19 04:20AM  Dr. Reddy's Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India Business Wire
Aug-01-19 10:41AM  New Strong Buy Stocks for August 1st Zacks
Jul-31-19 04:05PM  Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer Business Wire
Jul-30-19 09:14AM  Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y Zacks
05:14AM  Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market Business Wire
Jul-29-19 09:15AM  Dr. Reddys Q1 FY20 Financial Results Business Wire
Jul-23-19 06:27AM  Dr. Reddy's Laboratories Announces the Launch of Ramelteon Tablets, in the U.S. Market Business Wire
Jul-20-19 06:21AM  Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults PR Newswire
05:22AM  Dr. Reddys Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRA to Upsher-Smith Laboratories, LLC Business Wire
Jul-19-19 02:29AM  Dr. Reddys announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market Business Wire
Jul-12-19 11:40PM  Indivior loses appeal to block generic Suboxone opioid treatments Reuters
03:25PM  UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments Reuters
02:37PM  Indivior loses appeal to block generic Suboxone opioid treatments Reuters
Jul-10-19 05:13AM  Dr. Reddy's to release Q1 FY 20 results on July 29, 2019 Business Wire
Jul-09-19 03:23AM  Dr. Reddys Announces the Launch of the Over-the-counter Store Brand Equivalent of Mucinex® D Extended Release Tablets in Two Strengths in the U.S. Market Business Wire
Jul-03-19 04:42AM  Dr. Reddy's Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market Business Wire
Jun-28-19 03:16PM  Heres What Hedge Funds Think About Dr. Reddys Laboratories Limited (RDY) Insider Monkey
Jun-25-19 10:33AM  Top Indian Stocks Traded In The U.S Investopedia
06:23AM  Dr. Reddy's Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market Business Wire
Jun-22-19 08:53AM  Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market Business Wire
Jun-14-19 05:25PM  Dr. Reddy's Inks Deal to Sell Neurology Branded Products Zacks
01:38AM  Dr. Reddys Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC Business Wire
Jun-13-19 11:57PM  Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection) PR Newswire
Jun-12-19 06:29AM  Barclays Has New Plays for Healthcare Fans SmarterAnalyst
Jun-10-19 05:30PM  Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug Zacks
02:42AM  Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddys Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis Business Wire
Jun-06-19 10:33AM  BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady Zacks
Jun-04-19 01:42AM  Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F Business Wire
Jun-03-19 10:43AM  Dr. Reddy's Laboratories Announces the Re-Launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg in the U.S. Market Business Wire
May-22-19 07:48AM  New Strong Sell Stocks for May 22nd Zacks
May-20-19 03:06PM  Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates Zacks -6.02%
May-17-19 03:07PM  Dr. Reddys Laboratories Earnings: RDY Stock Dips Despite Q4 Beat InvestorPlace
10:58AM  Dr. Reddys Q4 & FY19 Financial Results Business Wire
07:32AM  Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat Zacks
May-15-19 01:59AM  Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market Business Wire
May-13-19 04:24PM  Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store? Zacks
May-06-19 03:11AM  Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market Business Wire
May-01-19 05:57PM  URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately PR Newswire
Apr-20-19 09:03PM  Heres What Hedge Funds Think About Dr. Reddys Laboratories Limited (RDY) Insider Monkey
Apr-17-19 12:05PM  Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019 Business Wire
Apr-15-19 12:08PM  Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs Zacks
Apr-13-19 12:34PM  Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio Business Wire
Apr-03-19 08:19AM  The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 08:15AM  Is India's 7.3% Growth Worth An Investment? Benzinga
01:54AM  Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddys Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology Business Wire
Apr-01-19 04:46PM  Supernus' ADHD Candidate Positive in 4th Phase III Study Zacks
Mar-28-19 08:32AM  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) Zacks
Mar-27-19 04:05AM  Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market Business Wire
Mar-20-19 10:38AM  Top Ranked Momentum Stocks to Buy for March 20th Zacks
Mar-01-19 07:20AM  Factors of Influence in 2019, Key Indicators and Opportunity within Vanda Pharmaceuticals, Range Resources, Fortune Brands Home & Security, Dr. Reddy's Laboratories, BWX Technologies, and K12 New Research Emphasizes Economic Growth GlobeNewswire
Feb-27-19 06:16PM  Watching for Signs of Global Risk Events Investopedia
Feb-20-19 12:01PM  Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation Business Wire
Feb-12-19 03:00AM  Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market Business Wire
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks
12:51AM  Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling Business Wire
Feb-01-19 10:17AM  Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America Business Wire
09:27AM  Dr. Reddy's (RDY) Earnings Rise in Q3, Sales Increase Y/Y Zacks
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. As of March 31, 2019, it had six late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company also offers diabetes nutrition drink under the Celevida brand name. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.